KR20190040320A - 항-그렘린-1 (grem1) 항체 및 폐동맥 고혈압을 치료하기 위한 그의 사용 방법 - Google Patents

항-그렘린-1 (grem1) 항체 및 폐동맥 고혈압을 치료하기 위한 그의 사용 방법 Download PDF

Info

Publication number
KR20190040320A
KR20190040320A KR1020197008656A KR20197008656A KR20190040320A KR 20190040320 A KR20190040320 A KR 20190040320A KR 1020197008656 A KR1020197008656 A KR 1020197008656A KR 20197008656 A KR20197008656 A KR 20197008656A KR 20190040320 A KR20190040320 A KR 20190040320A
Authority
KR
South Korea
Prior art keywords
ser
antibody
gly
seq
grem1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197008656A
Other languages
English (en)
Korean (ko)
Inventor
단 칼로손
로리 씨. 모튼
Original Assignee
리제너론 파아마슈티컬스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리제너론 파아마슈티컬스, 인크. filed Critical 리제너론 파아마슈티컬스, 인크.
Publication of KR20190040320A publication Critical patent/KR20190040320A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020197008656A 2016-08-29 2017-08-23 항-그렘린-1 (grem1) 항체 및 폐동맥 고혈압을 치료하기 위한 그의 사용 방법 Ceased KR20190040320A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662380562P 2016-08-29 2016-08-29
US62/380,562 2016-08-29
PCT/US2017/048137 WO2018044640A1 (en) 2016-08-29 2017-08-23 Anti-gremlin-1 (grem1) antibodies and methods of use thereof for treating pulmonary arterial hypertension

Publications (1)

Publication Number Publication Date
KR20190040320A true KR20190040320A (ko) 2019-04-17

Family

ID=59791160

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197008656A Ceased KR20190040320A (ko) 2016-08-29 2017-08-23 항-그렘린-1 (grem1) 항체 및 폐동맥 고혈압을 치료하기 위한 그의 사용 방법

Country Status (12)

Country Link
US (1) US20180057580A1 (enExample)
EP (1) EP3504238A1 (enExample)
JP (1) JP2019529371A (enExample)
KR (1) KR20190040320A (enExample)
CN (1) CN109641954A (enExample)
AU (1) AU2017320989A1 (enExample)
CA (1) CA3031783A1 (enExample)
EA (1) EA201990613A1 (enExample)
IL (1) IL264309A (enExample)
MA (1) MA46046A (enExample)
MX (1) MX2019002382A (enExample)
WO (1) WO2018044640A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11680101B2 (en) 2017-01-27 2023-06-20 Kymab Limited Anti-OPG antibodies
MX2022016403A (es) 2020-06-18 2023-04-11 Regeneron Pharma Formulaciones de anticuerpo de activina a y métodos para utilizarlas.
JP2024504124A (ja) * 2021-01-18 2024-01-30 スーチョウ・トランスセンタ・セラピューティクス・カンパニー・リミテッド 新規の抗グレムリン1抗体
AU2023258146A1 (en) * 2022-04-20 2024-09-05 Kantonsspital St. Gallen Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof
WO2024258870A2 (en) 2023-06-12 2024-12-19 Amgen Inc. Lymphotoxin beta receptor agonist binding proteins
CN117801109B (zh) * 2024-03-01 2024-05-03 再少年(北京)生物科技有限公司 iPS诱导定向分化成内皮祖细胞的方法及应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2437213A1 (fr) 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
US6573096B1 (en) 2000-04-01 2003-06-03 The Research Foundation At State University Of New York Compositions and methods for inhibition of cancer invasion and angiogenesis
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
US7411046B2 (en) 2005-08-02 2008-08-12 Arius Research Inc Cancerous disease modifying antibodies
US7420040B2 (en) 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
US9610356B2 (en) * 2011-12-12 2017-04-04 Pieris Pharmaceutical GmbH Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation
JP6400479B2 (ja) * 2012-10-29 2018-10-03 株式会社カルディオ 肺疾患特異的治療剤
KR20150129718A (ko) * 2013-03-14 2015-11-20 리제너론 파아마슈티컬스, 인크. Grem 1에 대한 인간 항체

Also Published As

Publication number Publication date
MA46046A (fr) 2019-07-03
WO2018044640A1 (en) 2018-03-08
US20180057580A1 (en) 2018-03-01
MX2019002382A (es) 2019-06-20
CA3031783A1 (en) 2018-03-08
CN109641954A (zh) 2019-04-16
AU2017320989A9 (en) 2019-07-11
AU2017320989A1 (en) 2019-02-07
IL264309A (en) 2019-02-28
EA201990613A1 (ru) 2019-07-31
EP3504238A1 (en) 2019-07-03
JP2019529371A (ja) 2019-10-17

Similar Documents

Publication Publication Date Title
KR101859911B1 (ko) 사람 gdf8에 대한 항체
KR102146692B1 (ko) 항-pdgfr-베타 항체 및 이의 용도
KR101781786B1 (ko) 사람 안지오포이에틴-2에 대한 고 친화성 사람 항체
KR101964031B1 (ko) 전구단백질 전환효소 서브틸리신 켁신-9 (PCSK9)의 억제제를 투여함으로써 지질단백질(a)의 농도를 낮추는 방법
KR102440044B1 (ko) 항-액티빈 a 항체 및 그의 용도
AU2013302925B2 (en) Anti-PCSK9 antibodies with pH-dependent binding characteristics
KR102641731B1 (ko) 에볼라 바이러스 당단백질에 대한 인간 항체
KR102337042B1 (ko) Pd-1에 대한 사람 항체
AU2016307430B2 (en) Anti-ANGPTL8 antibodies and uses thereof
KR101896129B1 (ko) 인간 tnf-유사 리간드 1a(tl1a)에 대한 인간 항체
KR102163136B1 (ko) 항-cd3 항체, cd3 및 cd20에 결합하는 이특이적 항원-결합 분자, 및 이들의 사용
KR102185516B1 (ko) Fel d1에 대한 사람 항체 및 그것의 사용방법
KR101842570B1 (ko) 사람 안지오포이에틴-유사 단백질 4에 대한 사람 항체
US20180008672A1 (en) Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension
KR20150127618A (ko) Nav1.7에 대한 사람 항체
CN113144195A (zh) 伴pcsk9功能获得性突变的常染色体显性高胆固醇血症的治疗方法
KR20150013359A (ko) Pcsk9에 대한 고친화성 사람 항체
KR20190040320A (ko) 항-그렘린-1 (grem1) 항체 및 폐동맥 고혈압을 치료하기 위한 그의 사용 방법
KR20150129718A (ko) Grem 1에 대한 인간 항체
KR20140069331A (ko) 항-ErbB3 항체 및 이의 용도
PH12014501730B1 (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
KR20190075133A (ko) 렙틴 수용체에 길항하는 항원-결합 단백질
KR20230051683A (ko) 액티빈 a 길항제를 사용한 심장 기능 장애 및 covid-19의 예방 및 치료 방법

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190326

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200824

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20221027

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230104

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20221027

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I